Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Ovarian Cancer | Research

CA125 Levels in BRCA mutation carriers – a retrospective single center cohort study

Authors: P Gebhart, CF Singer, D Gschwantler-Kaulich

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Ovarian cancer screening in BRCA1/2 mutation carriers utilizes assessment of carbohydrate antigen 125 (CA125) and transvaginal ultrasound (TVU), despite low sensitivity and specificity. We evaluated the association between CA125 levels, BRCA1/2 mutation status and menopausal status to provide more information on clinical conditions that may influence CA125 levels.

Methods

We retrospectively analyzed repeated measurements of CA125 levels and clinical data of 466 women at high risk for ovarian cancer. CA125 levels were compared between women with and without deleterious mutations in BRCA1/2. Pearson's correlation was used to determine the association between age and CA125 serum level. Differences in CA125 levels were assessed with the Mann–Whitney U test. The effect of BRCA1/2 mutation status and menopausal status on the change in CA125 levels was determined by Two-factor analysis of variance (ANOVA).

Results

The CA125 serum levels of premenopausal women (median, 13.8 kU/mL; range, 9.4 – 19.5 kU/mL) were significantly higher than in postmenopausal women (median, 10.4 kU/mL; range, 7.7 – 14.0 kU/mL; p < .001). There was no significant difference in the CA125 levels of BRCA mutation carriers and non-mutation carriers across all age groups (p = .612). When investigating the combined effect of BRCA1/2 mutation and menopausal status, variance analysis revealed a significant interaction between BRCA1/2 mutation status and menopausal status on CA125 levels (p < .001). There was a significant difference between the CA125 levels of premenopausal and postmenopausal women, with a large effect in BRCA mutation carriers (p < .001, d = 1.05), whereas in non-mutation carriers there was only a small effect (p < .001, d = 0.32).

Conclusion

Our findings suggest that hereditary mutations in BRCA1/2 affect the decline of CA125 levels with increasing age. To prove a definite effect of this mutation on the CA125 level, prospective trials need to be conducted to define new cut-off levels of CA 125 in mutation carriers and optimize ovarian cancer screening.
Literature
1.
Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–53.PubMedCrossRef
2.
Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–16.PubMedCrossRef
3.
Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening. Ann Oncol. 2016;27(suppl 5):v103–10.PubMedCrossRef
4.
Finch APM, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547–53.PubMedPubMedCentralCrossRef
5.
Conte C, Pelligra S, Sarpietro G, Montana GD, Della Corte L, Bifulco G, et al. Hereditary women's cancer: management and risk-reducing surgery. Medicina (Kaunas). 2023;59(2):300.
6.
Yoshida T, Takahashi K, Yamatani H, Takata K, Kurachi H. Impact of surgical menopause on lipid and bone metabolism. Climacteric. 2011;14(4):445–52.PubMedCrossRef
7.
Honigberg MC, Zekavat SM, Aragam K, Finneran P, Klarin D, Bhatt DL, et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA. 2019Dec 24;322(24):2411.PubMedPubMedCentralCrossRef
8.
Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Obstet Gynecol Surv. 2008Jan;63(1):32–3.CrossRef
9.
Mannis GN, Fehniger JE, Creasman JS, Vanessa LMAS, Beattie MS. Risk-reducing salpingo-oophorectomy and ovarian C screening in 1077 women after BRCA testing. JAMA Intern Med. 2013;173(2):96.PubMedPubMedCentralCrossRef
10.
Rosenthal AN, Fraser LSM, Philpott S, Manchanda R, Burnell M, Badman P, et al. Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom familial ovarian cancer screening study. J Clin Oncol. 2017;35(13):1411–20.PubMedPubMedCentralCrossRef
11.
Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34(1):33–47.PubMedCrossRef
12.
Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305(22):2295–302.PubMedCrossRef
13.
Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. The Lancet. 2016;387(10022):945–56.CrossRef
14.
Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. Cancer screening in the United States, 2017: a review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin. 2017;67(2):100–21.PubMedCrossRef
15.
Stirling D, Evans DGR, Pichert G, Shenton A, Kirk EN, Rimmer S, et al. Screening for familial ovarian cancer: Failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics System. J Clin Oncol. 2005;23(24):5589–96.CrossRef
16.
Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and ovarian cancer: a comprehensive review. Cancers (Basel). 2020;12(12):1–29.CrossRef
17.
Akinwunmi BO, Babic A, Vitonis AF, Cramer DW, Titus L, Tworoger SS, et al. Chronic medical conditions and CA125 levels among women without ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2018;27(12):1483.PubMedPubMedCentralCrossRef
18.
Sevinc A, Adli M, Kalender ME, Camci C. Benign causes of increased serum CA-125 concentration. Lancet Oncol. 2007;8(12):1054–5.PubMedCrossRef
19.
Singhal A, Lander E, Karachristos A, Daly E, Dowling P, Patel V, et al. Elevation of CA 125 and CA 19–9 in patients with end-stage liver disease. Int J Biol Markers. 2012;27(2):147–51.CrossRef
20.
Van CB, Valentin L, Van HC, Zhang J, Jurkovic D, Lissoni AA, et al. A novel approach to predict the likelihood of specific ovarian tumor pathology based on Serum CA-125: a multicenter observational study. Cancer Epidemiology and Prevention Biomarkers. 2011;20(11):2420–8.CrossRef
21.
Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ. Factors influencing serum ca125ii levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2001;10(5):489–93.PubMed
22.
Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, et al. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila). 2011;4(9):1401.PubMedCrossRef
23.
Babic A, Cramer DW, Kelemen LE, Köbel M, Steed H, Webb PM, et al. Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the ovarian cancer association consortium. Cancer Causes Control. 2017;28(5):459.PubMedPubMedCentralCrossRef
24.
Bon GG, Kenemans P, Dekker JJ, Hompes PG, Verstraeten RA, Van Kamp GJ, et al. Fluctuations in CA 125 and CA 15–3 serum concentrations during spontaneous ovulatory cycles. Hum Reprod. 1999;14(2):566–70.PubMedCrossRef
25.
Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJS, Soletormos G, Torre GC, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005;15(5):679–91.PubMedCrossRef
26.
Skates SJ, Greene MH, Buys SS, Mai PL, Brown P, Piedmonte M, et al. Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk – Combined results from two screening trials. Clin Cancer Res. 2017;23(14):3628–37.PubMedPubMedCentralCrossRef
27.
Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10(4):327–40.PubMedCrossRef
28.
Zhang L, Chen Y, Wang K. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Curr Probl Cancer. 2019;43(2):135–44.PubMedCrossRef
29.
Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer: a pilot randomised controlled trial. The Lancet. 1999;353(9160):1207–10.CrossRef
30.
Sasamoto N, Babic A, Rosner BA, Fortner RT, Vitonis AF, Yamamoto H, et al. Predicting circulating CA125 levels among healthy premenopausal women. Cancer Epidemiol Biomarkers Prev. 2019;28(6):1076.PubMedPubMedCentralCrossRef
31.
Hermsen BBJ, von Mensdorff-Pouilly S, Berkhof J, van Diest PJ, Gille JJP, Menko FH, et al. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. J Clin Oncol. 2007;25(11):1383–9.PubMedCrossRef
32.
Meden H, Fattani-Meiodi A. CA 125 in benign gynecological conditions. Int J Biol Markers. 1998;13(4):231–7.PubMedCrossRef
33.
Maiorana A, Cicerone C, Niceta M, Alio L. Evaluation of Serum CA 125 Levels in Patients with Pelvic Pain Related to Endometriosis. Biol Markers. 2007;22(3):200–2.CrossRef
34.
Oliveira MAP, Raymundo TS, Soares LC, Pereira TRD, Demôro AVE. How to Use CA-125 More Effectively in the Diagnosis of Deep Endometriosis. Biomed Res Int. 2017;2017.
35.
Kauppila A, Telimaa S, Ronnberg L, Vuori J. Placebo-controlled study on serum concentrations of CA-125 before and after treatment of endometriosis with danazol or high-dose medroxyprogesterone acetate alone or after surgery. Fertil Steril. 1988;49(1):37–41.PubMedCrossRef
36.
Santulli P, Streuli I, Melonio I, Marcellin L, M’Baye M, Bititi A, et al. Increased serum cancer antigen-125 is a marker for severity of deep endometriosis. J Minim Invasive Gynecol. 2015;22(2):275–84.PubMedCrossRef
37.
Costanian C, McCague H, Tamim H. Age at natural menopause and its associated factors in Canada: Cross-sectional analyses from the Canadian Longitudinal Study on Aging. Menopause. 2018;25(3):265–72.PubMedCrossRef
38.
Gold EB, Bromberger J, Crawford S, Samuels S, Greendale GA, Harlow SD, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol. 2001;153(9):865–74.PubMedCrossRef
39.
Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeilinger R, Pils D, Muhr D, et al. Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers. PLoS ONE. 2017;12(12):1–12.CrossRef
40.
Chen Y, Bancroft E, Ashley S, Arden-Jones A, Thomas S, Shanley S, et al. Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers. Fam Cancer. 2014;13(2):197–203.PubMedCrossRef
41.
Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril. 2013;99(6):1724–8.PubMedCrossRef
42.
Lin WT, Beattie M, Chen L may, Oktay K, Crawford SL, Gold EB, et al. Comparison of Age at Natural Menopause in BRCA1/2 Mutation Carriers With a Non–Clinic-Based Sample of Women in Northern California. Cancer. 2013;119(9):1652.
43.
Tea MKM, Weghofer A, Wagner K, Singer CF. Association of BRCA1/2 mutations with FMR1 genotypes: Effects on menarcheal and menopausal age. Maturitas. 2013;75(2):148–51.PubMedCrossRef
44.
Kępczyński Ł, Połatyńska K, Nykel A, Sałamunia J, Kałużewski T, Kużawczyk A, et al. Age of natural menopause onset in BRCA1/2 carriers – systematic review and meta-analysis. Prz Menopauzalny. 2020;19(4):171.PubMed
45.
Woodward ER, Sleightholme H V., Considine AM, Williamson S, McHugo JM, Cruger DG. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG. 2007;114(12):1500–9.
46.
Havrilesky LJ, Dinan M, Sfakianos GP, Curtis LH, Barnett JC, van Gorp T, et al. Costs, effectiveness, and workload impact of management strategies for women with an adnexal mass. J Natl Cancer Inst. 2015;107(1):322.PubMedCrossRef
47.
Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;319(6):595–606.PubMedCrossRef
48.
Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397(10290):2182.PubMedPubMedCentralCrossRef
Metadata
Title
CA125 Levels in BRCA mutation carriers – a retrospective single center cohort study
Authors
P Gebhart
CF Singer
D Gschwantler-Kaulich
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11116-6

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Study protocol

Protocol for a confirmatory trial of the effectiveness and safety of palliative arterial embolization for painful bone metastases

Research

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy

Study Protocol

Can we use a simple blood test to reduce unnecessary adverse effects from radiotherapy by timely identification of radiotherapy-resistant rectal cancers? MeD-Seq rectal study protocol

Research

Percutaneous transhepatic cholangial drainage or antibiotic therapy worsens response to immunotherapy in advanced cholangiocarcinoma

Research

Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1

Research

Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits